Bayer to Acquire Vividion for ~$2B
Shots: Vividion to receive $1.5B up front & $500M milestone while Bayer to get full rights to Vividion’s discovery platform which consists of chemoproteomic screening technology, a data portal, and a chemistry library. The transaction is expected to close in Q3’21 The acquisition will strengthen Bayer’s drug discovery capabilities & expand it into new modalities. …